<DOC>
	<DOCNO>NCT00364260</DOCNO>
	<brief_summary>The purpose study determine use Eprex , maintain hemoglobin within normal range , prevent delay progression leave ventricular mass growth .</brief_summary>
	<brief_title>A Safety Efficacy Study Epoetin Alfa Pre-dialysis Subjects .</brief_title>
	<detailed_description>Cardiovascular disease continue major cause morbidity mortality subject renal ( kidney ) disease . Left ventricular hypertrophy ( LVH ) correlate high risk cardiac cause mortality . In renal population , many factor show important development LVH , include anemia . This multicentre , open , control , randomize trial determine maintain hemoglobin within normal range delay progress leave ventricular mass growth . Additionally , study evaluate safety maintain hemoglobin within normal range pre-dialysis subject . The trial duration 24 month . Subjects randomize treatment arm receive Eprex therapy maintain hemoglobin 120-140 g/L . Subjects randomize control arm receive treatment unless hemoglobin fall less equal 90 g/L . Those subject treat maintain hemoglobin 90-105 g/L . The subject receive injection Eprex weekly maintain hemoglobin level within target range arm randomize . The subject receive treatment 24 month .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients decrease hemoglobin &gt; = 10 g/L within past 12 month current hemoglobin level 110135 g/L ( men ) 100135 g/L ( woman ) OR hemoglobin level 115125 g/L ( men ) 110120 g/L ( woman ) Have calculate creatinine clearance &lt; 80 mL/min &gt; 15 mL/min No uncontrolled hypertension ( diastolic blood pressure &gt; = 105 mm Hg average previous month ) No unstable angina cardiac procedure within past 12 month plan procedure No myocardial infarction past 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Anemia</keyword>
	<keyword>epoetin alfa</keyword>
</DOC>